Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD2 | Q9HC29 | 3/20 | 0.53 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31264263 | 1.00 | NOD2 (0.53) | NOD2NOD1L3MBTL1LMNAALOX15 | |
| SCHEMBL3498975 | 0.89 | NOD2 (0.52) | NOD2NOD1ALOX15KDM4EMAPT | |
| SCHEMBL1253237 | 0.89 | RXFP1 (0.56) | NOD2NOD1L3MBTL1LMNAALOX15 | |
| SCHEMBL6796925 | 0.84 | CA12 (0.49) | NOD2NOD1LMNAKDM4EMAPT | |
| SCHEMBL29834934 | 0.84 | L3MBTL1 (0.57) | L3MBTL1KDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4833633 | 0.84 | L3MBTL1 (0.57) | L3MBTL1KDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL21463709 | 0.83 | LMNA (0.47) | NOD2NOD1L3MBTL1LMNAALOX15 | |
| SCHEMBL6753155 | 0.83 | MCL1 (0.49) | NOD2NOD1LMNAKDM4EMAPT | |
| SCHEMBL3920560 | 0.83 | NOD2 (0.53) | NOD2NOD1ALOX15KDM4EMAPT | |
| SCHEMBL30492931 | 0.83 | MCL1 (0.49) | NOD2NOD1LMNAKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025129023-A1 | INDOLE AMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | RECTIFY PHARMACEUTICALS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-11027027-B2 | Pyridazinoindole compounds and methods for PET imaging | VANDERBILT UNIVERSITY (US) | 2021-06-08 | — | — | US | disclosed |
| US-11027027-B2 | Pyridazinoindole compounds and methods for PET imaging | VANDERBILT UNIVERSITY (US) | 2021-06-08 | — | — | US | disclosed |
| US-20160220704-A1 | PYRIDAZINOINDOLE COMPOUNDS AND METHODS FOR PET IMAGING | VANDERBILT UNIVERSITY | 2016-08-04 | — | — | US | disclosed |
| US-20160220704-A1 | PYRIDAZINOINDOLE COMPOUNDS AND METHODS FOR PET IMAGING | VANDERBILT UNIVERSITY | 2016-08-04 | — | — | US | disclosed |
| US-20160220704-A1 | PYRIDAZINOINDOLE COMPOUNDS AND METHODS FOR PET IMAGING | VANDERBILT UNIVERSITY | 2016-08-04 | — | — | US | disclosed |
| US-8841320-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY | 2014-09-23 | — | — | US | disclosed |
| US-8841320-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY | 2014-09-23 | — | — | US | disclosed |
| US-20130177502-A1 | Targeted, NIR Imaging Agents for Therapy Efficacy Monitoring, Deep Tissue Disease Demarcation and Deep Tissue Imaging | VANDERBILT UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130177502-A1 | Targeted, NIR Imaging Agents for Therapy Efficacy Monitoring, Deep Tissue Disease Demarcation and Deep Tissue Imaging | VANDERBILT UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
| US-8188116-B2 | Ligand/drug conjugates; near infrared radiation imaging; peripheral benzodiazepine receptor imaging; drug delivery; drug targets; cancer, metastasis | VANDERBILT UNIVERSITY (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188116-B2 | Ligand/drug conjugates; near infrared radiation imaging; peripheral benzodiazepine receptor imaging; drug delivery; drug targets; cancer, metastasis | VANDERBILT UNIVERSITY (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100278739-A1 | TARGETED, NIR IMAGING AGENTS FOR THERAPY EFFICACY MONITORING, DEEP TISSUE DISEASE DEMARCATION AND DEEP TISSUE IMAGING | VANDERBILT UNIVERSITY | 2010-11-04 | — | — | US | disclosed |
| US-7754884-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754884-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY (US) | 2010-07-13 | — | — | US | disclosed |
| US-20080031823-A1 | AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING | US GOVERNMENT - SECRETARY FOR THE ARMY | 2008-02-07 | — | — | US | disclosed |
| US-20080031823-A1 | AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING | US GOVERNMENT - SECRETARY FOR THE ARMY | 2008-02-07 | — | — | US | disclosed |
| US-6451795-B1 | CENTRAL NEURODEGENERATIVE DISEASES | SANOFI-SYNTHELABO (FR) | 2002-09-17 | — | — | US | disclosed |
| US-6395729-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | SANOFI-SYNTHELABO (FR) | 2002-05-28 | — | — | US | disclosed |
| US-6262045-B1 | TREATMENT OF ANXIETY; SLEEP DISORDER; EPILEPSY; SPASTICITY; MUSCLE CONTRACTURE OR AN EXTRAPYRAMIDAL SYNDROM; INDUCING OR MAINTAINING ANAESTHESIA | SANOFI-SYNTHELABO (FR) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080031823-A1 | AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING | TSPO, MKI67, CNR1 | NOD2 4387/4885NOD1 2368/4885L3MBTL1 2590/4885 |
| US-11027027-B2 | Pyridazinoindole compounds and methods for PET imaging | TSPO, SLC25A17, SLC19A2 | NOD2 1223/4885NOD1 824/4885L3MBTL1 4244/4885 |
| US-20160220704-A1 | PYRIDAZINOINDOLE COMPOUNDS AND METHODS FOR PET IMAGING | TSPO, SLC25A17, SLC19A2 | NOD2 1223/4885NOD1 824/4885L3MBTL1 4244/4885 |
| US-20100278739-A1 | TARGETED, NIR IMAGING AGENTS FOR THERAPY EFFICACY MONITORING, DEEP TISSUE DISEASE DEMARCATION AND DEEP TISSUE IMAGING | TSPO, MKI67, GABRA4 | NOD2 3836/4885NOD1 2233/4885L3MBTL1 2678/4885 |
| US-20130177502-A1 | Targeted, NIR Imaging Agents for Therapy Efficacy Monitoring, Deep Tissue Disease Demarcation and Deep Tissue Imaging | TSPO, MKI67, GABRA4 | NOD2 3836/4885NOD1 2233/4885L3MBTL1 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.